BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strik AS, Berends SE, Mathôt RA, D'Haens GR, Löwenberg M. Golimumab for moderate to severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2017;11:401-6. [PMID: 28276288 DOI: 10.1080/17474124.2017.1303376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Fousekis FS, Papamichael K, Kourtis G, Albani EN, Orfanidou A, Saridi M, Katsanos KH, Christodoulou DK. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann Gastroenterol 2022;35:1-7. [PMID: 34987282 DOI: 10.20524/aog.2021.0682] [Reference Citation Analysis]
2 Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector - A smart device for emergency cum personal therapy. Saudi Pharm J 2021;29:1205-15. [PMID: 34703373 DOI: 10.1016/j.jsps.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 20.3] [Reference Citation Analysis]